HYHuikang Yang

Huikang Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Huikang Yang has a total of 45 co-authors. Here are the top co-authors by number of shared publications:

  • Fen Zou

    Department of Urology The Second Affiliated Hospital School of Medicine South China University of Technology Guangzhou China

    3 shared publications
  • Jundong Lin

    Guangdong Provincial Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University

    2 shared publications
  • Li-Ming Zhang

    Guangzhou Key Laboratory of Flexible Electronic Materials and Wearable Devices, Key Laboratory for Polymeric Composite and Functional Materials of Ministry of Education, Guangdong Engineering Technology Research Centre for Functional Biomaterials, School of Materials Science and Engineering

    2 shared publications
  • Ruimeng Yang

    The Second Affiliated Hospital, School of Medicine, South China University of Technology

    2 shared publications
  • Weide Zhong

    Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People’s Hospital, Guangzhou Medical University, Guangzhou, China

    2 shared publications
  • Wenjie Xie

    Department of Urology The Second Affiliated Hospital School of Medicine South China University of Technology Guangzhou China

    2 shared publications

Latest Publications

  • Glutathione‐Responsive Two‐Dimensional Nanolock Induces Cuproptosis in Prostate Cancer via Synergistic Chemodynamic‐Photothermal Therapy

    by Muqi Chen, Wenjie Xie, Jiaquan Xu, Yuexian Yao, Jundong Lin, Biyan Wen, Xiaoyu Lin, Qishan Dai, Fen Zou, Huikang Yang, et al.

    Cuproptosis, a novel form of programmed cell death induced by intracellular copper overload, provokes mitochondrial tricarboxylic acid (TCA) cycle collapse and metabolic dysfunction. This process can be potentiated by reactive oxygen species (ROS)‐burst strategies, including chemodynamic therapy (CDT) and photothermal therapy (PTT). Given the pronounced reliance of aggressive prostate cancer (PCa) cells on TCA cycle energy metabolism, therapeutic approaches that sensitize malignancies to cuproptosis hold significant promise. This study develops a tumor‐targeted nanolock (HA@CuHPT‐IR780) by coordinating copper ions with a catechol ligand, incorporating the photosensitizer IR780, and functionalizing the surface with hyaluronic acid for enhanced tumor targeting. The nanolock remains stable in a “locked” state under normal physiological conditions but disassembles upon exposure to glutathione (GSH), concurrently depleting GSH while releasing 2,3,6,7,10,11‐hexahydroxytriphenylene (HPT), Cu + , and IR780. Liberated HPT elevates intracellular hydrogen peroxide (H 2 O 2 ) levels, and Cu + converts H 2 O 2 into cytotoxic hydroxyl radicals (•OH) via a Fenton‐like reaction. Near‐infrared (NIR) irradiation further amplifies ROS generation via a photothermal effect and disrupts mitochondrial metabolism to potentiate cuproptosis. In vitro and in vivo experiments confirm cuproptosis induction in PCa cells via synergistic chemodynamic‐photothermal therapy with minimal systemic toxicity. Collectively, this work proposes a promising multimodal therapeutic regimen for advanced PCa.

  • Open Access

    Bioinformatics-Driven Engineering of ROS-Responsive Dextran-block-Poly(propylene sulfide) Nanoparticles Functionalized with Folic Acid for Targeted Prostate Cancer Therapy

    by Yixun Zhang, Zhenguo Liang, Zeheng Tan, Jundong Lin, Xinqing Jiang, Xin Zhou, Yangjia Zhuo, Fen Zou, Ronghua Yang, Weide Zhong, et al.

    Prostate cancer (PCa) remains a significant challenge in oncology due to its complex pathogenesis and resistance to conventional therapies. By leveraging bioinformatics-guided insights, we identified folate hydrolase 1 (FOLH1) as a crucial biomarker with overexpression in various cancers, particularly PCa. Therefore, we prepared folate receptor-targeted reactive oxygen species (ROS)-responsive dextran-block-poly­(propylene sulfide) nanoparticles to enhance targeted therapeutic efficacy against PCa. The block copolymer was achieved using Cu­(I)-catalyzed “click” chemistry, followed by the successful conjugation of folic acid (FA). Characterization confirmed the nanoparticles’ ability to encapsulate doxorubicin (Dox) and respond to ROS, releasing the drug under oxidative conditions. In vitro studies demonstrated enhanced cellular uptake, increased ROS production, and superior cytotoxicity of FA-Dex-b-PPS-Dox in PC3 cells compared to free Dox and nontargeted Dex-b-PPS-Dox nanoparticles. Furthermore, FA-Dex-b-PPS-Dox significantly inhibited tumor cell migration and invasion, emphasizing its potential for comprehensive cancer therapy. In vivo efficacy was assessed using a PC3 tumor model, where FA-Dex-b-PPS-Dox notably reduced tumor volume and weight, with histological analyses confirming enhanced apoptosis and reduced cell proliferation. These findings underscore the promising potential of FA-Dex-b-PPS-Dox in providing a targeted, ROS-responsive therapeutic strategy for prostate cancer.


  • Open Access

    Folate Receptor-Targeted, ROS-Responsive Dextran-Block-Poly (propylene sulfide) Copolymer Nanoparticles: A Bioinformatics-Guided Approach for Prostate Cancer Therapy

    by Yixun Zhang, Zhenguo Liang, Zeheng Tan, Jundong Lin, Xinqing Jiang, Ruimeng Yang, Jian Zhang, Huijing Tan, Wenjie Xie, Yangjia Zhuo, et al.

    This study presents a novel approach in nanomedicine for targeted cancer therapy by leveraging folic acid-receptor (FR) interactions and reactive oxygen species (ROS)-responsive nanocarriers. Utilizing big data to advance nanomedicine, we developed an innovative amphiphilic conjugate, folic acid (FA) decorated dextran-block-poly copolymer (FA-Dex-b-PPS), designed to serve as ROS-responsive nanocarriers specifically for prostate cancer treatment. The chemical structure of FA-Dex-b-PPS was confirmed via Fourier transform infrared spectroscopy and proton nuclear magnetic resonance. The self-assembly into ROS-responsive nanoparticles and subsequent degradation were characterized through fluorescence spectroscopy, dynamic light scattering, and transmission electron microscopy. Therapeutic nanocarriers encapsulating doxorubicin (Dox) were prepared via dialysis, demonstrating efficient oxidant-triggered Dox release in vitro. Cytotoxicity assays revealed high biocompatibility, with cell survival rates exceeding 85% at 400 μg/mL. Confocal laser scanning microscopy confirmed the efficient internalization of FA-Dex-b-PPS-Dox nanoparticles by PC3 cells via FR-mediated endocytosis, surpassing non-targeted Dex-b-PPS-Dox nanoparticles. Furthermore, in vitro and in vivo xenograft mouse model analyses consistently demonstrated that FA-Dex-b-PPS-Dox nanoparticles exhibited superior anti-tumor efficacy against PC3 cells compared to non-targeted and free Dox counterparts. These findings underscore the potential of tumor-targeted, ROS-responsive nanocarriers in enhancing the efficacy of cancer therapy.

  • Open Access

    Theranostic Nanoparticles with Aggregation-Induced Emission and MRI Contrast Enhancement Characteristics as a Dual-Modal Imaging Platform for Image-Guided Tumor Photodynamic Therapy

    by Huikang Yang, Yufang He, Yan Wang, Ruimeng Yang, Nianhua Wang, Li-Ming Zhang, Meng Gao, Xinqing Jiang

    Introduction: Advanced tumor-targeted theranostic nanoparticles play a key role in tumor diagnosis and treatment research. In this study, we developed a multifunctional theranostic platform based on an amphiphilic hyaluronan/poly-(N-ϵ-carbobenzyloxy-L-lysine) derivative (HA-g-PZLL), superparamagnetic iron oxide (SPIO) and aggregation-induced emission (AIE) nanoparticles for tumor-targeted magnetic resonance (MR) and fluorescence (FL) dual-modal image-guided photodynamic therapy (PDT). Materials and Methods: The amphiphilic hyaluronan acid (HA) derivative HA-g-PZLL was synthesized by grafting hydrophobic poly-(N-ϵ-carbobenzyloxy-L-lysine) (PZLL) blocks onto hyaluronic acid by a click conjugation reaction. The obtained HA-g-PZLLs self-assembled into nanoparticles in the presence of AIE molecules and SPIO nanoparticles to produce tumor-targeted theranostic nanoparticles (SPIO/AIE@HA-g-PZLLs) with MR/FL dual-modal imaging ability. Cellular uptake of the theranostic nanoparticles was traced by confocal laser scanning microscopy (CLSM), flow cytometry and Prussian blue staining. The intracellular reactive oxygen species (ROS) generation characteristics of the theranostic nanoparticles were evaluated with CLSM and flow cytometry. The effect of PDT was evaluated by cytotoxicity assay. The dual-mode imaging ability of the nanoparticles was evaluated by a real-time near-infrared fluorescence imaging system and magnetic resonance imaging scanning. Results: The resulting theranostic nanoparticles not only emit red fluorescence for high-quality intracellular tracing but also effectively produce singlet oxygen for photodynamic tumor therapy. In vitro cytotoxicity experiments showed that these theranostic nanoparticles can be efficiently taken up and are mainly present in the cytoplasm of HepG2 cells. After internalization, these theranostic nanoparticles showed serious cytotoxicity to the growth of HepG2 cells after white light irradiation. Discussion: This work provides a simple method for the preparation of theranostic nanoparticles with AIE characteristics and MR contrast enhancement, and serves as a dual-modal imaging platform for image-guided tumor PDT.